2nd Vaccine Global Congress - also Virtual
This most authoritative vaccine congress will be held December 7-9 2008, in Boston MA, USA
Amsterdam, December 3, 2008 – Next week the Elsevier Journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 2nd Vaccine Global Congress in Boston MA, USA. For those people who cannot attend the congress in Boston, Elsevier is organizing the 1st Vaccine Virtual Congress powered by ON24, the leading provider of webcasting and virtual events solutions. This truly interactive event will allow people to sample the high-quality content and networking opportunities that the congress and exhibition provide from their desk.
Following the successful Vaccine Congress held in Amsterdam last year, the meeting in Boston will again serve as an authoritative international interface between academics in research and development, regulatory and governmental agencies, charities, and health and industry professionals. The 2nd Vaccine Global Congress is organized in collaboration with the International Society for Vaccines. To supplement a number of invited keynote speakers, multiple oral and poster presentations have been selected to cover all facets of vaccinology, including: human vaccines for infectious and non-infectious diseases, veterinary vaccines, adjuvants, drug delivery, production, safety and regulatory aspects.
In addition, for all of those who cannot join the congress in Boston, Elsevier is offering a taste of the 2nd Vaccine Global Congress by broadcasting live keynote presentations and related Q&A, scheduled on the 9th of December. People will be able to submit questions in real time, network and chat with their online peers, and navigate the show via a virtual fully interactive platform. Registration for the Vaccine Virtual Congress is free.
“As for last year, our aim is to provide a progressive state-of the-art report for scientists, governmental authorities and healthcare workers”, stated Floris de Hon, Publisher of Vaccine, “I am confident that together with the virtual information solution we offer, an event will be created that will assist in accelerating progress in the development of vaccines”.
Notes to editors:
If you are planning to attend the 2nd Vaccine Global Congress, December 7-9 2008, in Boston, MA, USA, we would be delighted to offer you a registration badge at no charge. A press room will be available and please contact the press office if you are interested in setting up interviews with key opinion leaders in the field of vaccines.
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation. About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 3269